7 citations
,
January 2013 in “European Urology” This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.
29 citations
,
March 2010 in “Cancer epidemiology” This study found that early-onset male pattern baldness was associated with a reduced relative risk of prostate cancer.
37 citations
,
April 2008 in “The Cochrane library” This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.
January 2009 in “Side effects of drugs annual” This chapter reviews drugs affecting blood coagulation and details the increased hemorrhage risk associated with warfarin interactions, liver disease, heart failure, and antiphospholipid antibodies but reports no new clinical results.
2 citations
,
January 2011 in “Clinical medicine insights” The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.